What is the ROCE (Return on Capital Employed) of Opthea this year?
The ROCE of Opthea is 25.68 undefined this year.
Opthea ROCE 2024
Opthea ROCE
25.68
Ticker
OPT.AX
ISIN
AU000000OPT2
WKN
A2AB8J
In 2024, Opthea's return on capital employed (ROCE) was 25.68, a -1,374.75% increase from the -2.01 ROCE in the previous year.
Opthea Aktienanalyse
What does Opthea do?
Opthea Ltd is a biopharmaceutical company specializing in the development of novel therapies for various eye diseases. The company was founded in 1985 in Melbourne, Australia as a spin-off from the Burnet Institute for Medical Research and Public Health. Since then, Opthea has become a leading company in ophthalmology and is researching innovative therapies that have the potential to improve the lives of millions of patients worldwide. Opthea's business model is to develop novel therapies for various eye diseases and market these therapies through partnerships with established pharmaceutical companies. The company focuses on developing therapies based on the inhibition of growth factors and other signaling pathways that promote the development of abnormal blood vessels and inflammation. This therapeutic principle offers a promising way to effectively treat various eye diseases. Opthea specializes in developing therapies for the treatment of wet age-related macular degeneration (AMD), which is the leading cause of severe visual impairment in older people. Opthea is developing a therapy aimed at inhibiting the excessive formation of blood vessels in the macula of the eye, which can impair vision. The drug called OPT-302 is used in combination therapies with existing treatments for wet AMD and has the potential to slow down the progression of the disease and improve vision. In addition to the therapy for wet AMD, Opthea is also researching therapy options for other eye diseases such as diabetic retinopathy, retinal vein occlusion, and corneal diseases. Opthea has filed numerous patents in this field and collaborates with various academic and clinical partners to advance the development of innovative therapies. Another important component of Opthea's business model is collaboration with established pharmaceutical companies. In 2020, Opthea entered into a licensing agreement with the pharmaceutical company Novartis, which includes exclusive distribution and marketing rights for the drug OPT-302 in Europe, Japan, and other countries outside of North America. This partnership allows Opthea to benefit from collaboration with an experienced and established partner while maximizing the potential of its innovative therapy. In summary, Opthea is a promising company in ophthalmology that specializes in the development of innovative therapies for various eye diseases. The company works closely with academic and clinical partners and leverages the advantages of partnerships with established pharmaceutical companies to maximize the potential of its therapies. With the therapy for wet AMD already in the pipeline, Opthea is expected to develop further therapy options in the future that will contribute to improving the lives of millions of patients worldwide. Opthea ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROCE Details
Unraveling Opthea's Return on Capital Employed (ROCE)
Opthea's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.
Year-to-Year Comparison
Analyzing Opthea's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.
Impact on Investments
Opthea's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.
Interpreting ROCE Fluctuations
Changes in Opthea’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.
Frequently Asked Questions about Opthea Stock
How has the ROCE (Return on Capital Employed) of Opthea developed compared to the previous year?
The ROCE of Opthea has increased by -1,374.75% decreased compared to the previous year.
What does a high ROCE (Return on Capital Employed) mean for investors of Opthea?
A high Return on Capital Employed (ROCE) indicates that Opthea has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.
What does a low ROCE (Return on Capital Employed) mean for investors of Opthea?
A low ROCE (Return on Capital Employed) can indicate that Opthea has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.
How does an increase in ROCE from Opthea impact the company?
An increase in the ROCE of Opthea can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.
How does a reduction in the ROCE of Opthea affect the company?
A decrease in ROCE of Opthea can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.
What are some factors that can influence the ROCE of Opthea?
Some factors that can affect Opthea's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.
Why is the ROCE of Opthea so important for investors?
The ROCE of Opthea is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.
What strategic measures can Opthea take to improve the ROCE?
To improve the ROCE, Opthea can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.
How much dividend does Opthea pay?
Over the past 12 months, Opthea paid a dividend of 0.15 USD . This corresponds to a dividend yield of about 62.36 %. For the coming 12 months, Opthea is expected to pay a dividend of 0 USD.
What is the dividend yield of Opthea?
The current dividend yield of Opthea is 62.36 %.
When does Opthea pay dividends?
Opthea pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Opthea?
Opthea paid dividends every year for the past 3 years.
What is the dividend of Opthea?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Opthea located?
Opthea is assigned to the 'Health' sector.
Wann musste ich die Aktien von Opthea kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Opthea from 2/24/2005 amounting to 0.15 USD, you needed to have the stock in your portfolio before the ex-date on 2/4/2005.
When did Opthea pay the last dividend?
The last dividend was paid out on 2/24/2005.
What was the dividend of Opthea in the year 2023?
In the year 2023, Opthea distributed 0 USD as dividends.
In which currency does Opthea pay out the dividend?
The dividends of Opthea are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Opthea
Our stock analysis for Opthea Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Opthea Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
